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A B S T R A C T
Objectives: Treatment choices for people with lung cancer may be inﬂuenced by contact and engagement with
lung cancer nurse specialists (LCNSs). We investigated how service factors, LCNS workload, and LCNS working
practices may inﬂuence the receipt of anticancer treatment.
Materials and methods: English National Lung Cancer Audit data and inpatient Hospital Episode Statistics for
109,079 people with lung cancer surviving 30 days from diagnosis were linked along with LCNS workforce
census data and a bespoke nationwide LCNS survey. Multinomial logistic regression was used to determine
adjusted relative risk ratios (RRRs) for receipt of anticancer therapies associated with LCNS assessment, LCNS
workforce composition, caseload, LCNS reported working practices, treatment facilities at the patients’ attending
hospitals, and the size of the lung cancer service.
Results: Assessment by an LCNS was the strongest independent predictor for receipt of anticancer therapy, with
early LCNS assessments being particularly associated with greater receipt of surgery (RRR 1.85, 95%CI
1.63–2.11). For people we considered clinically suitable for surgery, receipt was 55%. Large LCNS caseloads
were associated with decreased receipt of surgery among suitable patients (RRR 0.71, 95%CI 0.51–0.97) for
caseloads>250 compared to≤150. Reported LCNS working practices were associated with receipt of surgery,
particularly provision of psychological support (RRR 1.60, 95%CI 1.02–2.51) and social support (RRR 1.56,
95%CI 1.07–2.28).
Conclusion: LCNS assessment, workload, and working practices are associated with the likelihood of patients
receiving anticancer therapy. Enabling and supporting LCNSs to undertake key case management interventions
oﬀers an opportunity to improve treatment uptake and reduce the apparent gap in receipt of surgery for those
suitable.
1. Introduction
A diagnosis of lung cancer is often associated with a poor prognosis
because of its frequent identiﬁcation at an advanced disease stage and
the rapid decline in performance status; as such it has the highest
mortality of all cancers [1,2]. Improvement in survival in the UK has
been greater than in other high-income countries globally [3], although
relative survival is reported to be lower than in other parts of Europe
[4].
Increased uptake of treatment is crucial to drive improvements in
lung cancer survival. The 2016 National Lung Cancer Audit (NLCA)
reported improvements in the proportions of people with non-small-cell
lung cancer (NSCLC) undergoing surgery and those with small-cell lung
cancer (SCLC) receiving chemotherapy compared with those in pre-
vious years, but concluded that there was an unexplained variation in
surgical resection rates; the majority of hospital providers did not meet
a 60% target for the proportion of people receiving anticancer treat-
ment (in the form of surgery, chemotherapy or radiotherapy) [5].
Previous studies have identiﬁed speciﬁc hospital-provider and pa-
tient factors associated with inequalities in access and uptake of lung
cancer treatment across England [6–10], with similar characteristics
shown to have an inﬂuence internationally [11]. We have previously
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shown that such factors are also associated with a patient’s likelihood of
assessment by a lung cancer nurse specialist (LCNS) [12]. Guidelines
from the National Institute for Health and Care Excellence (NICE) re-
commend that patients have direct access to an LCNS for support
throughout the cancer pathway [13]; NLCA annual reports show im-
provement over time in the proportion of patients seen by a nurse
specialist, although recommended targets are not always met [14,15].
LCNSs have a crucial role in an individual’s cancer journey as experi-
enced professionals who case manage care, meet information needs,
manage symptom control issues, support patients and families in deci-
sion-making and readiness for treatment, and advocate patient wishes
within multidisciplinary settings [16,17]. However, whether these
working practices are directly linked with treatment uptake has not
been assessed.
To understand how contact with an LCNS may inﬂuence a person’s
decision for anticancer therapy, we assessed whether factors aﬀecting
LCNS workload are associated with receipt in an English lung cancer
population and, in particular, those who could be expected to undergo
surgical resection.
2. Materials and methods
NLCA data capturing cases of lung cancer diagnosed at hospital
providers across the UK were linked with the 2011 National Cancer
Action Team (NCAT) census of specialist cancer nurse workforces in
England by hospital provider (National Health Service trust) code [18],
and hospital episode statistics (HES) inpatient data according to NHS
number provided the oﬃcial record of admission episodes to NHS
hospital trusts. We included NLCA patients from 146 English hospital
providers who were ﬁrst seen between January 2007 and December
2011 at a service with NCAT workforce data veriﬁed by regional cancer
network (Appendix A). People diagnosed through death certiﬁcates
only and those with mesothelioma or carcinoid were not included. We
also excluded people who died within 30 days of their diagnosis as it is
likely they were at a very advanced stage upon diagnosis and therefore
did not have an opportunity to commence anticancer therapy or be
assessed by an LCNS.
A combination of the NLCA and HES—where dates of surgery,
chemotherapy and radiotherapy are recorded [19]—was used to assign
people to one of four exclusive categories: surgery with or without
chemotherapy or radiotherapy, chemotherapy with or without radio-
therapy, radiotherapy alone, or no anticancer therapies. All che-
motherapy and radiotherapy treatments were then combined for sub-
group analysis. Whether radiotherapy was of curative or palliative
intent was not distinguished because detail to deﬁnitively determine
this was not available.
NLCA and HES data classiﬁed specialist anticancer treatment facil-
ities available at each hospital provider: thoracic surgery facilities
(surgical), chemotherapy available without surgery (chemotherapy), or
neither treatment option onsite (no specialty). A hospital provider with
a specialty in chemotherapy was deﬁned by at least 75% of patients
receiving an anticancer drug at a service where they were also ﬁrst
seen, as previously described by Powell et al. [8]. NLCA data were used
to determine the annual number of new lung cancer patients seen by a
service in each year of the study, with an average providing a measure
of service size.
Using NCAT national census information on salary bands, we cate-
gorized the composition of LCNS workforces as Band 7 only, Bands 6–7
or Band 8 included. Each hospital provider’s LCNS caseload was cal-
culated as the total number of patients ﬁrst seen there divided between
the LCNS whole-time equivalent (WTE) workforce, assuming people
followed the lung cancer pathway at that same site [12]. Evidence
about whether the patient was assessed by an LCNS was obtained from
NLCA data, as was the timing of assessment relative to diagnosis. Where
no information was entered, patients were separately categorized as
missing and were included in the analyses.
3. Statistical analysis
There were three or more possibilities for the receipt of treatment.
We performed multinomial logistic regression using Stata (SE15) to
calculate the relative risk ratio (RRR) of receipt of speciﬁed therapies
relative to a base group of no anticancer therapy. The RRR is sometimes
interpreted as a conditional odds ratio or called a multinomial odds
ratio. Cluster robust standard errors were derived to calculate con-
ﬁdence intervals for RRRs using regional cancer networks to account for
hierarchical groupings of observations. Exposure variables were in-
dividual patient-recorded LCNS assessment and its timing, salary band
composition of the LCNS workforce, the average LCNS caseload at the
service, treatment facilities available, and the annual service size.
Univariate analyses were performed, and models were mutually ad-
justed for exposures as well as patient co-morbidity deﬁned using HES
IP ICD-10 codes [20], age at diagnosis, sex, socioeconomic quintile
(based on income deprivation domain for the national population),
performance status, and cancer stage as recorded in the NLCA.
As receipt of treatment is inﬂuenced by a number of factors that we
were unable to control for, we conducted a subgroup analysis restricted
to people who we deemed were suitable for surgery based on clinical
guidelines and author expertise (RBH, PB) and the clinical data avail-
able to us. Suitability for surgery was deﬁned as a recorded perfor-
mance status of 0–1 (World Health Organization, WHO) and NSCLC
stages I, II, IIIA (Union for International Cancer Control versions 6 and
7) [20].
For people who were suitable for surgery, receipt of therapy was
also assessed according to LCNS-reported experiences of working
practice by using responses from a bespoke e-survey disseminated to all
LCNSs in the UK’s National Lung Cancer Forum for Nurses (NLCFN)
(Appendix B). A total of 230 survey responses from 105 hospital pro-
viders were collected; the response rate was estimated to be 76% of
WTE LCNS positions in England [21], with a completion rate for
questions presented here ranging from 83% to 100%. Responses were
linked to the combined dataset based on the NHS trust code where the
LCNS worked. Routine provision of key LCNS interventions was deﬁned
as oﬀered to more than 70% of patients along the clinical pathway from
pre-diagnosis up to and including the point of treatment. As the role of
the LCNS can vary widely, aﬃrmative responses were aggregated ac-
cording to hospital provider to present the perspective of at least one
LCNS and an indication of key interventions available to the patient
population served.
4. Results
A total of 109,079 patients in our study population were diagnosed
with lung cancer between 2007 and 2011 and survived 30 days; of
these, 31.8% did not receive anticancer therapy, 33.9% received che-
motherapy, 18.3% received radiotherapy, and 16.1% received surgery
(Table 1).
4.1. LCNS workforce factors
Assessment by an LCNS was associated with increased RRR in re-
ceipt of each therapy group compared to not being assessed (surgery
RRR 1.98, chemotherapy RRR 2.18, radiotherapy RRR 1.84 after ad-
justments). LCNS assessment before/at diagnosis also resulted in an
increased RRR in each therapy group compared to assessment after
diagnosis, particularly for surgery (RRR 1.85 95%CI 1.63–2.11). Where
workforces included a Band-8 LCNS, there was an associated 27% re-
duction in RRR for receipt of chemotherapy (RRR 0.73, 95%CI
0.54–0.97), whilst average caseloads of> 250 patients per LCNS were
associated with a 26% increase in the RRR for receipt of radiotherapy
(RRR 1.26, 95%CI 1.00–1.59).
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4.2. Hospital-provider factors
Specialist anticancer treatment facilities were associated with
greater RRRs for receipt of each therapy group compared to services
with no specialty, availability of surgical facilities resulting in the
greatest associations (surgery RRR 1.80; chemotherapy RRR 1.81;
radiotherapy RRR 1.47 after adjustments). Availability of specialist
chemotherapy facilities was associated with a greater RRR for receipt of
chemotherapy (RRR 1.39, 95%CI 1.10–1.75) and radiotherapy (RRR
1.27, 95%CI 1.05–1.53), but no association was observed for receipt of
surgery. The annual service size was not associated with receipt.
4.3. Clinical suitability for surgical resection
Our subgroup criteria identiﬁed 17,213 patients (15.8% of all pa-
tients) suitable for surgery based on cancer stage and performance
status; 54.7% of people within this subgroup received surgery and
11.1% received no anticancer therapy (Table 2). For those suitable for
surgery, timing of LCNS assessment before/at diagnosis was strongly
associated with its receipt (RRR 1.68, 95%CI 1.36–2.07). Large LCNS
caseloads of> 250 new and surviving patients were associated with
lower RRR for receipt of surgery (RRR 0.71, 95%CI 0.51–0.97). Surgical
facilities were associated with a 60% increase in RRR compared to no
specialty (RRR 1.60, 95%CI 1.22–2.08), whilst services which saw 265
new patients per year were associated with receipt of the alternative
therapy option of chemotherapy or radiotherapy (RRR 1.32, 95%CI
1.01–1.71).
The association between LCNS-reported working practices and re-
ceipt of treatment was analyzed in 13,588 people who were suitable for
surgery, survived 30 days, and were represented by a response to a
national LCNS survey (Table 3). Availability of administrative support
was not associated with receipt of surgery, nor were provision of
proactive management, holistic needs assessment or investigation
management. Provision of health promotion was associated with a 29%
increase in RRR for surgery (RRR 1.29, 95%CI 1.01–1.65), whilst rou-
tine provision of social support was associated with a 56% increase in
receipt of surgery (RRR 1.56, 95%CI 1.07–2.28). Where psychological
support was routinely oﬀered, there was an associated increase in RRR
of receiving surgery (RRR 1.60, 95%CI 1.02–2.51) and the alternative
therapy options (RRR 1.44, 95%CI 1.15–1.81). Where LCNS teams re-
ported readiness to challenge any member within the multidisciplinary
team, there was an associated increase in the RRR for receipt of the
alternative therapy options (RRR 1.44, 95%CI 1.07–1.93), although
receipt of surgery did not reach signiﬁcance (RRR 1.49, 95%CI
0.93–2.39).
5. Discussion
Advanced nursing practice in cancer care oﬀers tremendous ad-
vantages through provision of cancer-speciﬁc expertise, leadership and
continuity across the whole care pathway. Despite their complex
skillsets, few data exist to quantify the impact of LCNSs on clinical
outcomes, and methods to do so require cautious interpretation.
Utilizing a large dataset representative of people with newly diagnosed
lung cancer [22], linked to hospital records and survey data, we ob-
served that assessment by an LCNS, assessment before/at diagnosis, and
the availability of specialist surgical facilities at a hospital provider
were the strongest independent predictors from resource-speciﬁc fac-
tors for the receipt of anticancer therapy. This observation was parti-
cularly true for receipt of surgery. Where the individual may be con-
sidered suitable for surgery, caseloads> 250 new and surviving
patients per LCNS were associated with reduced likelihood of surgery,
whilst provision of key interventions were associated with greater re-
ceipt.
Table 1
Lung cancer nurse specialist (LCNS) workload factors and their associations with receipt of anticancer therapy.
Total No therapy Receipt of surgery Receipt of chemotherapy Receipt of radiotherapy
n= 109,079 n=34,729 n=17,459 n=36,951 n=19,940
Freq % % % RRRa (95% CI) % RRRa (95% CI) % RRRa (95% CI)
Assessed by LCNS
No 4,730 4.3 8.0 3.3 1 2.0 1 3.3 1
Yes 70,904 65.0 57.3 65.4 1.98 (1.11–3.53) 70.7 2.18 (1.24–3.82) 68.9 1.84 (1.17–2.87)
Missing 33,445 30.7 36.0 31.3 1.73 (1.32–2.26) 27.3 2.14 (1.67–2.75) 27.8 1.72 (1.41–2.10)
First LCNS assessment
After diagnosis 30,578 28.0 28.4 20.2 1 30.1 1 31.1 1
Before/at diagnosis 36,995 33.9 25.7 41.5 1.85 (1.63–2.11) 37.8 1.27 (1.14–1.42) 34.9 1.16 (1.05–1.28)
Missing 41,506 38.1 47.2 38.3 1.41 (0.93–2.14) 32.1 0.74 (0.52–1.07) 34.0 0.81 (0.56–1.18)
LCNS workforce
Band 7 only 47,244 43.3 43.7 44.0 1 44.4 1 40.9 1
Bands 6–7 46,677 42.8 42.7 41.6 0.94 (0.76–1.16) 42.5 0.97 (0.78–1.20) 45.5 1.15 (0.97–1.35)
Band 8 included 15,158 13.9 14.9 14.4 0.81 (0.57–1.14) 13.0 0.73 (0.54–0.97) 13.7 0.96 (0.73–1.25)
Total LCNS caseload
≤150 patients 22,673 20.8 21.7 21.1 1 20.9 1 37.3 1
151–250 61,218 56.1 56.4 56.3 0.97 (0.82–1.14) 56.8 1.08 (0.87–1.33) 96.9 1.09 (0.91–1.30)
> 250 25,188 23.1 23.2 22.5 0.96 (0.73–1.25) 22.2 1.00 (0.78–1.28) 40.0 1.26 (1.00–1.59)
Treatment facilities
No specialty 27,499 25.2 29.4 23.7 1 22.8 1 24.3 1
Surgical 29,646 27.2 24.0 31.9 1.80 (1.42–2.28) 28.4 1.81 (1.45–2.26) 26.8 1.47 (1.20–1.80)
Chemotherapy 51,934 47.6 47.8 44.4 1.22 (0.95–1.56) 48.8 1.39 (1.10–1.75) 48.9 1.27 (1.05–1.53)
Annual service size
< 175 new LC patients 39,797 36.5 37.5 37.6 1 36.7 1 34.1 1
175–264 32,959 30.2 30.5 28.4 0.83 (0.63–1.09) 29.8 0.87 (0.67–1.15) 32.8 1.05 (0.89–1.24)
≥265 36,323 33.3 33.3 34.0 0.89 (0.73–1.08) 33.5 0.95 (0.79–1.15) 33.1 1.03 (0.86–1.23)
LC, lung cancer.
a Relative risk ratio adjusted for LCNS assessment and timing, workforce banding, average caseload size per LCNS, therapy availability and service size, as well as
patient’s age, sex, performance status, stage, comorbidity, and socioeconomic deprivation. Clustered by English Regional Cancer Network.
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5.1. Strengths and limitations
Our robust multinomial models are adjusted for patient socio-
demographic and disease factors that may be important confounders, as
well as organizational factors such as caseload and service specialty. To
address immortal time bias, the analysis was restricted to patients
surviving 30 days post-diagnosis. To address diﬀerences in therapy
suitability within a heterogeneous lung cancer population, subgroup
criteria were selected according to clinical suitability for surgery.
Linkage to a nationwide LCNS survey adds further insight into LCNS
working practices at the level of hospital provider; however, aggrega-
tion of responses may not represent the experiences of all LCNSs or their
caseloads. Those who did not respond to the survey may suﬀer greater
time pressures.
Table 2
Lung cancer nurse specialist (LCNS) workload factors and their associations with receipt of anticancer therapy among patients considered suitable for surgery.
Total No therapy Receipt of surgery Chemotherapy/radiotherapy
n= 17,213 n=1,910 n=9,417 n=5,886
Freq % % % RRRa (95% CI) % RRRa (95% CI)
Assessed by LCNS
No 549 3.2 5.5 3.4 1 2.1 1
Yes 13,040 75.8 67.9 74.6 1.74 (0.93–3.26) 80.1 1.68 (0.93–3.01)
Missing 3,624 21.1 26.6 22.0 1.20 (0.85–1.96) 17.8 1.43 (0.99–2.06)
First LCNS assessment
After diagnosis 4,500 26.1 27.7 22.2 1 32.0 1
Before/at diagnosis 8,039 46.7 37.2 49.3 1.68 (1.36–2.07) 45.7 1.08 (0.91–1.29)
Missing 4,674 27.2 35.0 28.6 1.27 (0.82–1.96) 22.3 0.64 (0.41–1.01)
LCNS workforce
Band 7 only 7,049 41.0 43.9 43.6 1 41.9 1
Bands 6–7 7,377 42.9 40.6 42.7 1.00 (0.82–1.23) 43.8 1.12 (0.94–1.34)
Band 8 included 2,427 14.1 15.5 13.7 0.79 (0.54–1.15) 14.3 0.93 (0.59–1.48)
Total LCNS caseload
≤150 patients 3,583 20.8 18.3 21.7 1 20.2 1
151–250 9,747 56.6 57.3 56.5 0.83 (0.66–1.04) 56.7 0.92 (0.76–1.10)
> 250 3,883 22.6 24.5 21.8 0.71 (0.51–0.97) 23.1 0.86 (0.65–1.16)
Treatment facilities
No specialty 4,016 23.3 26.8 21.9 1 24.5 1
Surgical 5,241 30.4 24.8 32.9 1.60 (1.22–2.08) 28.3 1.27 (0.96–1.68)
Chemotherapy 7,956 46.2 48.4 45.2 1.15 (0.86–1.55) 47.2 1.04 (0.84–1.28)
Annual service size
< 175 new LC patients 5,923 34.4 36.3 35.1 1 32.8 1
175–264 5,202 30.2 32.8 28.8 0.88 (0.71–1.10) 31.6 1.00 (0.80–1.27)
≥265 6,088 35.4 30.9 36.1 1.12 (0.90–1.40) 35.7 1.32 (1.01–1.71)
LC, lung cancer.
a Relative risk ratio adjusted for LCNS assessment and timing, workforce banding, average caseload size per LCNS, therapy availability and service size, as well as
patient’s age, sex, performance status, stage, comorbidity, and socioeconomic deprivation. Clustered by English Regional Cancer Network.
Table 3
Lung cancer nurse specialist (LCNS) reported working practices and their associations with receipt of anticancer therapy among patients considered suitable for
surgery.
Total No therapy Receipt of surgery Chemotherapy/radiotherapy
Freq % % % RRRa (95%CI) % RRRa (95%CI)
Suitable for surgery (n) 17,213 1,910 9,417 5,886
Patients represented by survey response (n) 13,588 1,393 7,466 4,729
Administrative support available 6,792 50.0 48.2 50.6 1.10 (0.86–1.39) 49.5 1.01 (0.83–1.22)
Patients represented by survey response (n) 13,041 1,337 7,137 4,567
Proactive management routinely provided 11,059 84.8 83.4 84.0 1.06 (0.79–1.43) 86.4 1.21 (0.85–1.72)
Holistic needs assessment routinely provided 11,901 91.3 89.1 91.7 1.27 (0.83–1.95) 91.3 1.28 (0.73–2.23)
Health promotion routinely provided 11,733 90.0 87.2 90.7 1.29 (1.01–1.65) 89.7 1.23 (0.90–1.67)
Investigation management routinely provided 12,392 95.0 94.2 94.7 1.22 (0.85–1.73) 95.7 1.19 (0.85–1.64)
Psychological support routinely provided 12,225 93.7 90.9 93.9 1.60 (1.02–2.51) 94.3 1.44 (1.15–1.81)
Social support routinely provided 12,834 98.4 98.1 98.4 1.56 (1.07–2.28) 98.5 1.31 (0.91–1.88)
Patients represented by survey response (n) 7,782 826 4,225 2,731
LCNS conﬁdent challenging all MDT members 6,366 81.8 76.0 82.4 1.49 (0.93–2.39) 82.6 1.44 (1.07–1.93)
MDT, multidisciplinary team. Routine provision of intervention deﬁned as oﬀered by at least one LCNS at service to more than 70% of their caseload from pre-
diagnosis to treatment. Negative response RRR=1; aﬃrmative responses presented.
a Relative risk ratio adjusted for LCNS assessment and timing, workforce banding, average caseload size per LCNS, therapy availability and service size, as well as
patient’s age, sex, performance status, stage, comorbidity, and socioeconomic deprivation. Clustered by English Regional Cancer Network.
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Our analyses support LCNS assessments as an important aspect in
improving the receipt of treatment, although we could not distinguish
in our data whether contact with an LCNS was a consequence of a
decision to start treatment, even when the LCNS assessment preceded
treatment. Other resource-related factors were assessed to further elu-
cidate the impact of the LCNS workforce on receipt of treatment.
We found missing data on LCNS assessment for 31% of all patients.
It has previously been shown that the percentage of missing data re-
duced during the study period from 32% in 2007 to 10% in 2011 [12],
which may introduce bias through diﬀerences in working practices over
time. The number of people without an initial LCNS assessment is re-
assuringly low relative to those assessed or those missing data; how-
ever, this discrepancy may overestimate the impact of the initial LCNS
assessment, and we considered further measures of LCNS involvement
and working practice on receipt of treatment.
The linked dataset of people surviving 30 days included a total of
17,549 people who received surgery, of whom 21.5% did not have a
recorded performance status and 17.9% were missing a complete
cancer stage entry. People suitable for surgery without a recorded
performance status or cancer stage were not included in the restricted
analysis, although our inclusion criteria provided the highest propor-
tion of recipients compared to more liberal deﬁnitions.
5.2. Hospital provider context and receipt of anticancer therapy
People were more likely to be in receipt of therapy if ﬁrst seen in a
service with specialist anticancer treatment facilities. This was similarly
true when the people considered were restricted to those suitable for
surgery, with the speciﬁc ﬁnding that specialist surgical facilities were
associated with greater receipt of surgery. A potential explanation is
that resources at such services may focus on patients who have the
potential to beneﬁt most from therapy, yet this raises questions of in-
equality and adds to studies that identify discrepancies in patient re-
section rates according to the proximity of surgical facilities [6,9].
5.3. LCNS assessment and receipt of anticancer therapy
We have previously shown that receipt of treatment is associated
with LCNS assessment and early timing of assessment [12]. Here, we
determined the impact of service factors and LCNS working practices on
treatment receipt, and we restricted analyses to those who should be
considered suitable for surgery. The observation that resection was
more likely if assessed by an LCNS before/at diagnosis may reﬂect a
discrepancy in patient conﬁdence and knowledge around surgical op-
tions when LCNS assessment and opportunity for intervention precedes
diagnosis [20,23]. LCNSs have excellent understanding of patient
context and requirements to improve eligibility for therapies, and they
act as a constant supportive presence [16]; this is particularly important
when there may be anxiety regarding treatment risks [23]. This analysis
provides evidence that timely LCNS assessment before/at diagnosis
oﬀers the best chance for everyone with a lung cancer diagnosis to
receive the most appropriate therapy.
5.4. LCNS working practices and receipt of anticancer therapy
Inclusion of Band-8 LCNSs reduced the chances of receipt of che-
motherapy in the overall population, whilst the proportion of people
who did not receive therapy was also relatively large. It is possible that
nurses may be more receptive to an individual’s preference for no
therapy, supporting their decision and advocating it within multi-
disciplinary settings [16]. The conﬁdence required to support alter-
native decisions is likely an attribute of highly qualiﬁed and experi-
enced LCNSs [24].
In the subgroup analysis, associations were found with the key LCNS
roles of health promotion, psychological support and social support
(e.g. signposting ﬁnancial advice), providing evidence that the ability
to support patients and direct them to further sources of assistance can
increase the likelihood of surgical resection. LCNS conﬁdence within
the multidisciplinary team was associated with increased patient re-
ceipt of other therapies in the suitability subgroup, suggesting that
LCNS conﬁdence and multidisciplinary team inclusivity are important
in encouraging patients’ receipt of treatment, although its inﬂuence on
receipt of surgery in those with underlying suitability did not reach
conﬁdence levels.
Administrative support was not associated with diﬀerences in re-
ceipt of surgery for those suitable, where provision may be expected to
be associated with increased receipt, particularly as the pressure of
large caseloads are associated with reduced receipt. However, nurses
frequently go beyond their contractual hours to avoid pressures that
could aﬀect patient outcomes. Such dedication may obscure the true
impact of administrative support on patients’ receipt of treatment.
5.5. Improving treatment uptake
The 2016 NLCA report notes improvement in recent years in the
number of surgical operations in people with NSCLC, but notes sub-
stantial variation across hospital providers [5]. Though clinical detail
was limited, we identiﬁed people who were broadly suitable for surgery
(16% of our cohort), yet only 55% received it. Improving uptake in
suitable patients alone presents an opportunity to improve upon
treatment rates and highlights the gap between suitability and patient
preference.
Where surgery was a suitable option, likelihood of receipt was al-
most 30% lower at services with LCNS caseloads> 250 compared to
those where caseloads were ≤150 people. These data indicate that the
largest caseloads impede decisions for surgery and may not oﬀer suf-
ﬁcient time to appease concerns regarding treatment risks [23], re-
gardless of suitability.
In 2014, The LCNS workforce was estimated at 263 WTE positions
in England [21], equating to caseloads of 117 new patients, with 47
more having survived the preceding year at a 1-year survival rate of
38% [5], totalling 164 patients on each LCNS caseload if shared equally
between all WTE positions. This ﬁgure is likely to vary drastically be-
tween providers and regions; indeed 23% of our English cross-section
were seen where caseloads were>250 people. We recommend en-
suring that WTE positions represent 1% of the expected new lung
cancer incidence, enabling caseloads of ≤150 managed patients (new
and surviving), closely aligned to NLCFN guidance (new only) [25].
Caseload pressure may also be reduced by assistance from clinical
support workers and through LCNS delegation of routine clerical tasks
to care coordinators [26]. Reducing caseload pressures could oﬀer
suﬃcient time for well-informed individual treatment decisions and
assure access to psychological and social support, and could allow
further LCNS focus on symptom and pathway management to facilitate
optimal treatment. The relationship between specialist nurse staﬃng
levels and optimal caseload is a challenge to simulate in a complex
patient group; our ﬁndings can contribute to current and future models
[27,28].
6. Conclusion
Championing the LCNS role is an appropriate strategy to improve
treatment rates, as contact and working practices are associated with
receipt of treatment, potentially via improved patient comprehension of
the disease and engagement with options. We propose that enabling
and supporting LCNSs to undertake key case-management duties, whilst
monitoring WTE working hours relative to manageable caseload sizes,
could reduce workload pressures suﬃciently to improve treatment
uptake in all lung cancer diagnoses, highlighted in those who are
clinically suitable. Future studies should further elucidate patient rea-
sons for refusal of optimal treatment strategies.
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